The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.
|Articles|June 25, 2020
FDA Authorizes 15-Minute Antibody Testing Kit
Author(s)Kevin Kunzmann
The finger-prick test showed 98.8% specificity for novel coronavirus in assessments including 1500 patients.
Advertisement
The US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to Virtality Diagnostics for a rapid
The diagnostic test, which requires a drop of blood from a finger prick, delivers results in 15 minutes, according to the company.
As an antibody test, it is capable of measuring the body’s immune response and determining whether a person’s body produced an antibody response to SARS-CoV-2 infection—indicating both past exposure to and infection by novel coronavirus.
The Virality test’s efficacy was evidenced in a recent series of trials involving 1500-plus patients from multiple sites in the US. The test exhibited 98.8% specificity for novel coronavirus, and a high sensitivity (94.9%) for patients tested at least 2 weeks from symptom onset.
These results indicate the test is performatively better than a majority of current rapid LFA tests authorized by the FDA, as well as some ELISA tests being primarily used for SARS-CoV-2 antibody detection.
The company anticipates it could provide a million-plus antibody test kits daily. David A. Spiegel, MD, PhD, chief scientific advisor and co-founder of Virality, emphasized the company’s aim in contributing to the gamut of available, reliable antibody tests during the pandemic.
“Nearly everyone who recovers from COVID develops IgG and IgM antibodies, and it is likely that these antibodies reflect some degree of immunity to the disease,” he said in a
Advertisement
Related to this article
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
Irkutsk anti-plague institute death prompts quarantines and conflicting official accounts.
A laboratory technician at a Siberian anti-plague institute has died of pneumonia of unknown cause, prompting quarantines and contact monitoring while Russian officials stop short of confirming plague.
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season.
In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.